Optimised Prime: A Transformative RNA-LNP Vaccine Composition that Scales

Time: 9:30 am
day: Day One AM


  • LNP formulation and physicochemical characteristics with both messenger RNA (mRNA) and self-amplifying RNA (saRNA) 
  • In vivo immunogenicity of RNA-LNP vaccines against influenza A and SARS-CoV-2  
  • Overcoming scale-up and process development challenges in vaccine development